Workflow
AlphaTON’s Claude Connector Accelerates User Shift Away From Big Tech AI Practices That Steal Ideas and Data
Globenewswire· 2026-01-30 13:30
AlphaTON allow users run Anthropic’s Claude Agentic Tools right from the AlphaTON Claude Connector Telegram App, recognized as the most cost-effective way to build a "Private AI Cloud" at home.Miami, FL, Jan. 30, 2026 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) ("AlphaTON" or the "Company"), announced today The AlphaTON Claude Connector is a platform designed to bridge Anthropic’s Claude AI with the TON (The Open Network) blockchain. It primarily operates through a Telegram interface, allowing ...
Reliance Global Group Reports 72% Increase in Health Insurance Policies Written Through RELI Exchange During 2025 Open Enrollment
Globenewswire· 2026-01-30 13:30
Policy growth reflects strong execution and expanding distribution across RELI Exchange platform Broker network expanded from approximately 65 to approximately 300 since acquisition in 2022 LAKEWOOD, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Reliance Global Group, Inc. (Nasdaq: EZRA) (the “Company”) today announced strong operating momentum across its insurance operations, highlighted by a significant year-over-year increase in health insurance policies written through its RELI Exchange, LLC subsidiary during t ...
Saratoga Investment Corp. Prices Public Offering of $100 Million 7.50% Notes Due 2031
Globenewswire· 2026-01-30 13:30
NEW YORK, NY, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Saratoga Investment Corp. (the “Company”) (NYSE: SAR) today announced that it has priced an underwritten public offering of $100.0 million in aggregate principal amount of 7.50% unsecured notes due 2031 (the “Notes”). The offering is subject to customary closing conditions and is expected to close on February 6, 2025. The Notes will mature on February 6, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company’s option on o ...
IperionX – December 2025 Quarterly Report
Globenewswire· 2026-01-30 13:30
CHARLOTTE, N.C., Jan. 30, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to present its quarterly report for the period ending December 31, 2025. Highlights during and subsequent to the end of the quarter include: Commercial operations Commissioning Complete: Equipment and systems for both titanium powder production and component manufacturing have been fully commissioned at the Titanium Manufacturing Campus in Virginia.Manufacturing Capacity Expansion: Advanced manu ...
Red River Bancshares, Inc. Reports Fourth Quarter 2025 Financial Results
Globenewswire· 2026-01-30 13:30
Core Insights - Red River Bancshares, Inc. reported record-high net income for both the fourth quarter and the full year of 2025, with net income of $11.4 million for Q4 and $42.8 million for the year, representing increases of 5.7% and 24.9% respectively compared to previous periods [2][3][5]. Financial Performance - For Q4 2025, net income was $11.4 million, or $1.73 per diluted share, compared to $10.8 million, or $1.63 per diluted share in Q3 2025 [2]. - The return on assets for Q4 2025 was 1.38%, and the return on equity was 12.60% [2]. - For the full year 2025, net income was $42.8 million, or $6.38 per diluted share, compared to $34.2 million, or $4.95 per diluted share in 2024 [3]. Operational Highlights - The fourth quarter of 2025 saw a record-high quarterly net income, improved net interest margin, and solid growth in loans, deposits, and assets [4]. - Loans held for investment increased to $2.25 billion, up $75.6 million, or 3.5% from Q3 2025 [17]. - Total assets reached $3.35 billion, an increase of $136.5 million, or 4.2% from the previous quarter, driven by a $124.6 million increase in deposits [4][22]. Deposits and Loans - Total deposits as of December 31, 2025, were $2.96 billion, up $124.6 million, or 4.4% from September 30, 2025, primarily due to seasonal inflows from public entity customers [22]. - The company experienced robust loan growth, with loans HFI increasing 8.4% for the year 2025 [7]. Stockholder Returns - The company paid a quarterly cash dividend of $0.15 per common share in Q4 2025, with a total cash dividend of $0.54 per share for the year, a 50% increase from $0.36 in 2024 [4][5]. Stock Repurchase Program - The company renewed and increased its stock repurchase program for 2026, authorizing up to $10.0 million for share buybacks [4]. Interest Income and Margin - Net interest income for Q4 2025 was $28.2 million, a 5.0% increase from Q3 2025, with a net interest margin FTE of 3.51%, up 8 basis points [9][6]. - The average rate on new and renewed loans was 6.72% for Q4 2025 [9]. Credit Quality - Nonperforming assets (NPAs) totaled $3.5 million as of December 31, 2025, an increase of 44.9% from the previous quarter, with a ratio of NPAs to assets at 0.11% [20]. - The allowance for credit losses (ACL) was $23.4 million, with a ratio of ACL to loans HFI at 1.04% [21].
Hudson Technologies Provides Update on Status of Defense Logistics Agency Contract
Globenewswire· 2026-01-30 13:30
WOODCLIFF LAKE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Hudson Technologies, Inc. (NASDAQ: HDSN) a leading provider of innovative and sustainable refrigerant products and services to the Heating, Ventilation, Air Conditioning, and Refrigeration industry – and one of the nation’s largest refrigerant reclaimers – today provided an update on the status of its previously announced contract with the United States Defense Logistics Agency (“DLA”) awarded in October 2025 and set to commence in July 2026 (the “2025 ...
BCB Bancorp, Inc. Reports Net Loss of $12.0 Million in Fourth Quarter 2025
Globenewswire· 2026-01-30 13:30
BAYONNE, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported a net loss of $12.0 million for the fourth quarter of 2025, compared to net income of $4.3 million in the third quarter of 2025, and net income of $3.3 million for the fourth quarter of 2024. The Company’s loss per diluted share for the fourth quarter was ($0.73) compared to earnings per diluted share of $0.22 in the preceding quarter and ...
Pacific Financial Corp Reports Fourth Quarter 2025 Earnings of $3.1 Million, or $0.31 per Diluted Share; Declares Quarterly Cash Dividend of $0.15 per Share
Globenewswire· 2026-01-30 13:30
ABERDEEN, Wash., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Pacific Financial Corporation (OTCQX: PFLC), (“Pacific Financial”) or (the “Company”), the holding company for Bank of the Pacific (the “Bank”), reported net income of $3.1 million, or $0.31 per diluted share for the fourth quarter of 2025, compared to $3.5 million, or $0.35 per diluted share for the third quarter of 2025, and $2.2 million, or $0.21 per diluted share for the fourth quarter of 2024. The current quarter’s net income relative to the prior quar ...
Actelis Networks Receives Significant Expansion Order from Major European Natural Gas Operator, Continuing Critical Infrastructure Modernization
Globenewswire· 2026-01-30 13:30
Follow-on order of approximately $150,000 validates Actelis' solution and demonstrates growing adoption in energy sector; deployment supports homeland security objectives through modernization of critical infrastructure monitoring and cyber-hardened connectivitySUNNYVALE, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it h ...
Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value
Globenewswire· 2026-01-30 13:30
New Taipei City, Taiwan, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced updated statistical analyses for key blood biochemical markers from its Phase II ...